Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation

Radiotherapy and Oncology

Volumn 109, Issue 2, 2013, Pages 286-292

  Laban, Simon ^a   Steinmeister, Leonhard ^a   Gleißner, Lisa ^a   Grob, Tobias J ^a   Grénman, Reidar ^b   Petersen, Cordula ^a   Gal, Andreas ^a   Knecht, Rainald ^a   Dikomey, Ekkehard ^a   Kriegs, Malte ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Head and neck squamous cell carcinoma; Irradiation; MAPK; Radiosensitization; Sorafenib

Indexed keywords

DOUBLE STRANDED DNA; MITOGEN ACTIVATED PROTEIN KINASE; SORAFENIB;

ADULT; AGED; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; DOSE CALCULATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IONIZING RADIATION; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; RADIOSENSITIZATION;

HEAD AND NECK SQUAMOUS CELL CARCINOMA; IRRADIATION; MAPK; RADIOSENSITIZATION; SORAFENIB;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DNA REPAIR; HEAD AND NECK NEOPLASMS; HUMANS; NIACINAMIDE; PHENYLUREA COMPOUNDS; RADIATION-SENSITIZING AGENTS; RAF KINASES;

EID: 84889568057     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2013.07.003     Document Type: Article

References (37)

1. S. Laban, C.J. Wang, A. Munscher, S. Tribius, P. Schafhausen, and R. Knecht Molecular targeting agents in the context of primary chemoradiation strategies Head Neck 35 5 2013 738 746
2. J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578
3. P. Chinnaiyan, S. Huang, and G. Vallabhaneni Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva) Cancer Res 65 2005 3328 3335
4. S.M. Huang, and P.M. Harari Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis Clin Cancer Res 6 2000 2166 2174
5. L. Myllynen, T. Rieckmann, and J. Dahm-Daphi In tumor cells regulation of DNA double strand break repair through EGF receptor involves both NHEJ and HR and is independent of p53 and K-Ras status Radiother Oncol 101 2011 147 151
6. M. Toulany, U. Kasten-Pisula, and I. Brammer Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair Clin Cancer Res 12 2006 4119 4126
7. M. Kriegs, U. Kasten-Pisula, and T. Rieckmann The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining DNA Repair (Amst) 9 2010 889 897
8. S.M. Wilhelm, C. Carter, and L. Tang BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109
9. R.J. Motzer, N. Agarwal, and C. Beard NCCN clinical practice guidelines in oncology: kidney cancer J Natl Compr Canc Netw 7 2009 618 630
10. A.B. Benson 3rd, T.A. Abrams, and E. Ben-Josef NCCN clinical practice guidelines in oncology: hepatobiliary cancers J Natl Compr Canc Netw 7 2009 350 391
11. S.K. Williamson, J. Moon, and C.H. Huang Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420 J Clin Oncol 28 2010 3330 3335
12. G.R. Blumenschein, B.S. Glisson, and C. Lu Final results of a phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN) ASCO 30 2012 5592 Meeting abstracts
13. A. Yaromina, M. Krause, and H. Thames Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation Radiother Oncol 83 2007 304 310
14. M. Heravi, N. Tomic, and L. Liang Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model Anticancer Drugs 23 2012 525 533
15. Y.C. Kuo, W.C. Lin, and I.T. Chiang Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-kappaB expression in vitro and in vivo Biomed Pharmacother 66 2012 12 20
16. J.P. Plastaras, S.H. Kim, and Y.Y. Liu Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation Cancer Res 67 2007 9443 9454
17. A.W. Suen, S. Galoforo, and B. Marples Sorafenib and radiation: a promising combination in colorectal cancer Int J Radiat Oncol Biol Phys 78 2010 213 220
18. A. Yadav, B. Kumar, T.N. Teknos, and P. Kumar Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins Mol Cancer Ther 10 2011 1241 1251
19. E. Dikomey, J. Dahm-Daphi, I. Brammer, R. Martensen, and B. Kaina Correlation between cellular radiosensitivity and non-repaired double-strand breaks studied in nine mammalian cell lines Int J Radiat Biol 73 1998 269 278
20. W. Eicheler, D. Zips, A. Dorfler, R. Grenman, and M. Baumann Splicing mutations in TP53 in human squamous cell carcinoma lines influence immunohistochemical detection J Histochem Cytochem 50 2002 197 204
21. R. Grenman, T.E. Carey, and K.D. McClatchey In vitro radiation resistance among cell lines established from patients with squamous cell carcinoma of the head and neck Cancer 67 1991 2741 2747
22. T.J. Grob, U. Heilenkotter, and S. Geist Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer Breast Cancer Res Treat 134 2012 561 567
23. N.F. Schlecht, M. Brandwein-Gensler, and G.J. Nuovo A comparison of clinically utilized human papillomavirus detection methods in head and neck cancer Mod Pathol 24 2011 1295 1305
24. R. Corvo, W. Giaretti, and G. Sanguineti Chemoradiotherapy as an alternative to radiotherapy alone in fast proliferating head and neck squamous cell carcinomas Clin Cancer Res 3 1997 1993 1997
25. R. Corvo, W. Giaretti, and G. Sanguineti In vivo cell kinetics in head and neck squamous cell carcinomas predicts local control and helps guide radiotherapy regimen J Clin Oncol 13 1995 1843 1850
26. P.I. Poulikakos, C. Zhang, G. Bollag, K.M. Shokat, and N. Rosen RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Nature 464 2010 427 430
27. M. Roring, R. Herr, and G.J. Fiala Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling EMBO J 31 2012 2629 2647
28. L. Liu, Y. Cao, and C. Chen Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 Cancer Res 66 2006 11851 11858
29. S.M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J.M. Llovet, and M. Lynch Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling Mol Cancer Ther 7 2008 3129 3140
30. M. Hornecker, B. Blanchet, and B. Billemont Saturable absorption of sorafenib in patients with solid tumors: a population model Invest New Drugs 30 5 2012 1991 2000
31. D. Strumberg, J.W. Clark, and A. Awada Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors Oncologist 12 2007 426 437
32. K.D. Olsen Reexamining the treatment of advanced laryngeal cancer Head Neck 32 2010 1 7
33. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
34. W.D. Heyer, K.T. Ehmsen, and J. Liu Regulation of homologous recombination in eukaryotes Annu Rev Genet 44 2010 113 139
35. M. Heim, M. Scharifi, and J. Zisowsky The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines Anticancer Drugs 16 2005 129 136
36. K.K. Ang, Q.E. Zhang, and D.I. Rosenthal A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC) ASCO 29 2011 5500 Meeting abstracts
37. J. Giralt, A. Fortin, and R. Mesia A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN) ASCO 30 2012 5502 Meeting abstracts